NCT06517212View on ClinicalTrials.gov

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

August 31, 2029

Study Completion Date

December 31, 2030

Conditions
Breast CancerBreast NeoplasmsBreast Cancers
Interventions
DRUG

Tirzepatide

Patients will receive tirzepatide once weekly for up to 2 years.

Trial Locations (1)

75246

RECRUITING

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER